Details
Translated title of the contribution | Innovations change the world: What are the benefits of innovative drugs in the treatment of psychiatric disorders? |
---|---|
Original language | German |
Pages (from-to) | 244-252 |
Number of pages | 9 |
Journal | Gesundheitsokonomie und Qualitatsmanagement |
Volume | 18 |
Issue number | 5 |
Publication status | Published - Oct 2013 |
Abstract
Psychiatric disease constitutes a large burden for society. The social costs of psychiatric disorders surpass cancer and cardiac diseases. Many patients affected by psychiatric disease are still in the working age, thus causing high indirect illness costs. Despite the substantial advances in the treatment of psychiatric patients and the development of new drugs in recent years, there is still considerable room for improvement in treatment outcomes, compliance and side-effect profiles in psychiatric therapies. Hence, there is a need for new innovative psychiatric drugs. However, long development times and low success rates compared to other therapeutic areas as well as accelerating cost containment measures hinder the development of innovative psychiatric drugs. In order to reduce the time and costs of developing innovative drugs, the research and development process of psychiatric drugs has to be rationalized. In addition regulatory authorities and sickness funds should reflect the increasing importance of psychiatric disorders and the need for innovative therapies. Only then will the development of new drugs in the field of psychiatric disorders progress according to its medical and economic importance.
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: Gesundheitsokonomie und Qualitatsmanagement, Vol. 18, No. 5, 10.2013, p. 244-252.
Research output: Contribution to journal › Article › Research › peer review
}
TY - JOUR
T1 - Innovationen verändern die Welt
T2 - Der Beitrag von Arzneimittelinnovationen in der Therapie psychischer Erkrankungen?
AU - Graf Von Der Schulenburg, J. M.
AU - Kuhlmann, A.
PY - 2013/10
Y1 - 2013/10
N2 - Psychiatric disease constitutes a large burden for society. The social costs of psychiatric disorders surpass cancer and cardiac diseases. Many patients affected by psychiatric disease are still in the working age, thus causing high indirect illness costs. Despite the substantial advances in the treatment of psychiatric patients and the development of new drugs in recent years, there is still considerable room for improvement in treatment outcomes, compliance and side-effect profiles in psychiatric therapies. Hence, there is a need for new innovative psychiatric drugs. However, long development times and low success rates compared to other therapeutic areas as well as accelerating cost containment measures hinder the development of innovative psychiatric drugs. In order to reduce the time and costs of developing innovative drugs, the research and development process of psychiatric drugs has to be rationalized. In addition regulatory authorities and sickness funds should reflect the increasing importance of psychiatric disorders and the need for innovative therapies. Only then will the development of new drugs in the field of psychiatric disorders progress according to its medical and economic importance.
AB - Psychiatric disease constitutes a large burden for society. The social costs of psychiatric disorders surpass cancer and cardiac diseases. Many patients affected by psychiatric disease are still in the working age, thus causing high indirect illness costs. Despite the substantial advances in the treatment of psychiatric patients and the development of new drugs in recent years, there is still considerable room for improvement in treatment outcomes, compliance and side-effect profiles in psychiatric therapies. Hence, there is a need for new innovative psychiatric drugs. However, long development times and low success rates compared to other therapeutic areas as well as accelerating cost containment measures hinder the development of innovative psychiatric drugs. In order to reduce the time and costs of developing innovative drugs, the research and development process of psychiatric drugs has to be rationalized. In addition regulatory authorities and sickness funds should reflect the increasing importance of psychiatric disorders and the need for innovative therapies. Only then will the development of new drugs in the field of psychiatric disorders progress according to its medical and economic importance.
KW - costs
KW - innovation
KW - psychiatric disorders
KW - psychiatric drugs
KW - regulation
UR - http://www.scopus.com/inward/record.url?scp=84886872603&partnerID=8YFLogxK
U2 - 10.1055/s-0033-1355492
DO - 10.1055/s-0033-1355492
M3 - Artikel
AN - SCOPUS:84886872603
VL - 18
SP - 244
EP - 252
JO - Gesundheitsokonomie und Qualitatsmanagement
JF - Gesundheitsokonomie und Qualitatsmanagement
SN - 1432-2625
IS - 5
ER -